Research Studies for Multiple Sclerosis
This study is being done to see how effective and tolerable ublituximab is when given to people who had been receiving different anti-CD20 therapy for relapsing multiple sclerosis. Ublituximab is approved by the US Food and Drug Administration (FDA) with the name BRIUMVI®, for adults with relapsing forms of multiple sclerosis.
The investigational drug is a Bruton Tyrosine Kinase Inhibitor, a selective therapy aiming to reduce MS relapses. The trials will last up to 30 months (core study), plus a 5-year extension part. During the core study, participants will have approximately 15 study site visits, including a follow-up appointment.
You could be able to take part in these trials if you’re aged 18-55, have been diagnosed with MS (Relapsing Remitting or Secondary Progressive) and have had 1 documented relapse in the last year, or 2 in the last 2 years.
Do you have Relapsing-Remitting Multiple Sclerosis (RRMS)?
There is a new clinical trial of the investigational oral drug PIPE-307 that is being tested to see if it can help adults with RRMS.
It is believed that PIPE-307 will bind a muscarinic receptor on a specific brain cell that may potentially result in new myelin formulation (remyelination). The goal of this study is to test the safety and behavior of PIPE-307 in your body when taken daily by mouth for 6 months. The study will also test whether treatment with PIPE-307 affects your MS symptoms and how well you can function in daily life.
If you qualify, you will be in the study for up to 34 weeks and will visit the study site about 7 times. To potentially qualify, you must:
If you would like to learn more about the VISTA study, please contact the Research Department at 781-551-5812 opt. 2
The EFC17504/FREXVIVA trial is a Phase III clinical trial designed to test how the investigational study drug works and whether it is safe.
The investigational study drug (frexalimab, which is administered intravenously) will be compared to placebo (which looks like the investigational study drug but has no therapeutic effect). The purpose of this trial is to compare the investigational study drug or placebo to see if the investigational study drug can possibly delay disease progression in patients diagnosed with secondary progressive multiple sclerosis (SPMS).
You will have a 2 in 3 chance of receiving frexalimab. The length of study treatment will be between 27 to 51 months, depending on the moment when you start your participation. You may qualify for this study if you:
The EFC17919/FREXALT trial is a Phase III clinical trial designed to assess the safety and efficacy of the investigational study drug against an existing treatment medication in RMS, teriflunomide.
The investigational study drug (frexalimab, which is administered intravenously) will be compared to teriflunomide (oral tablets). The purpose of this trial is to compare the investigational study drug to teriflunomide to see if the investigational study drug can possibly reduce the relapse frequency, and/or delay disease progression patients diagnosed with RMS.
Participants will be randomly selected to receive frexalimab or teriflunomide. The duration of study treatment will be between 20 to 40 months, depending on the moment when you start your participation. You may qualify for this study if you:
See if one of our Research Studies may be a good fit for you...
Call us at 781-551-5812 or fill out the online appointment form...